FDA Recalls Three Hematology Analyzers
The FDA issued a Class I recall of three hematology analyzers – Beckman Coulter DxH 800, DxH 600, and DxH 900 – after reports...
Walking Speed Predicts Frailty, Survival, and Other Outcomes in Older Patients With Blood Cancers
Walking speed was a reliable indicator of frailty among older patients with blood cancers, and this frailty measure was a more accurate predictor of...
Tagraxofusp Leads to High Response Rates in Blastic Plasmacytoid Dendritic Cell Neoplasm
Ninety percent of patients with previously untreated blastic plasmacytoid dendritic cell neoplasm (BPDCN) responded to treatment with tagraxofusp, a CD123-targeted agent previously known as...
Study Finds Standard R-CHOP Bests Dose-Adjusted EPOCH-R in DLBCL
In an update from the phase III intergroup Alliance/CALGB 50303 trial, treatment with frontline dose-adjusted (DA) EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab) failed...
TKIs Linked to Increased Cardiovascular and Arteriothrombotic Events in Chronic-Phase CML
In patients with chronic-phase chronic myeloid leukemia (CML), treatment with tyrosine kinase inhibitors (TKIs) has been shown to increase the risk of cardiovascular and...
FDA to Close Its Controversial Medical Device Reporting Program
In what is being called a victory for patients and consumers, the U.S. Food and Drug Administration (FDA) said that it is ending its...
New ASH Congressional Fellow, Accepting Submissions for 2019 ASH Annual Meeting, and more
Next ASH Congressional Fellow Is Bound for Capitol Hill
Zachary Kiser, PhD, has been selected by the American Society of Hematology (ASH) to be the...
FDA Expands Ivosidenib’s Indication to Newly Diagnosed AML
On May 2, 2019, The U.S. Food and Drug Administration (FDA) approved an expanded indication for the IDH1 inhibitor ivosidenib to include the treatment...
Post-Transplant Pembrolizumab Consolidation Improves PFS in Relapsed/Refractory Hodgkin Lymphoma
In patients with high-risk, relapsed/refractory classical Hodgkin lymphoma (cHL) who have undergone autologous hematopoietic cell transplantation (AHCT), consolidation therapy with the PD-1 inhibitor pembrolizumab...
New Study Supports “R2” Regimen in Previously Untreated Follicular Lymphoma
The combination of lenalidomide and rituximab, known as the R2 regimen, improved progression-free survival (PFS), time to next treatment (TTNT), and complete response (CR)...
Current Issue
August 2019, Volume 5, Issue 10
This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.
